Castle Biosciences Reports Second Quarter 2023 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 22c; Offers FY23 Revenue Guidance
August 2, 2023 4:25 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.70), $0.22 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $50.14 million versus the consensus estimate of $44.24 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2023 revenue of $180 million, versus the... More
